AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.930
-0.030 (-1.01%)
At close: Feb 27, 2026, 4:00 PM EST
2.963
+0.033 (1.13%)
After-hours: Feb 27, 2026, 6:28 PM EST
AC Immune Employees
As of December 31, 2024, AC Immune had 172 total employees, including 133 full-time and 39 part-time employees. The number of employees increased by 11 or 6.83% compared to the previous year.
Employees
172
Change (1Y)
11
Growth (1Y)
6.83%
Revenue / Employee
$31,878
Profits / Employee
-$524,035
Market Cap
289.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 172 | 11 | 6.83% | 133 | 39 |
| Dec 31, 2023 | 161 | 5 | 3.21% | 133 | 28 |
| Dec 31, 2022 | 156 | 7 | 4.70% | 126 | 30 |
| Dec 31, 2020 | 149 | 17 | 12.88% | 125 | 24 |
| Dec 31, 2019 | 132 | 28 | 26.92% | 115 | 17 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Puma Biotechnology | 172 |
| X4 Pharmaceuticals | 143 |
| Abeona Therapeutics | 136 |
| Nautilus Biotechnology | 124 |
| Adlai Nortye | 123 |
| ALX Oncology Holdings | 44 |
| Fennec Pharmaceuticals | 32 |
ACIU News
- 2 months ago - AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD - Seeking Alpha
- 2 months ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 2 months ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 4 months ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire
- 7 months ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 10 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 11 months ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire